Reed Jobs Is Building a Cancer Moonshot and Doesn't Want Your Sympathy

Reed Jobs, the 33-year-old son of Steve Jobs and Laurene Powell Jobs, does not particularly want to be introduced by his surname. That is understandable. When you have a last name that is synonymous with a particular kind of Silicon Valley mythology, everything you do gets filtered through it. He would rather you focus on what Yosemite, his cancer research organisation, is actually trying to accomplish: curing cancer in his lifetime.

That is not a modest goal, and Reed Jobs does not frame it modestly. In a profile published by TechCrunch, he describes Yosemite's mission in the bluntest terms possible. Not manage cancer. Not improve outcomes. Cure it. The organisation he runs is focused specifically on applying machine learning and computational biology to identify which drug combinations work against which tumour types, with an emphasis on finding patterns in data that human researchers would not have the capacity to spot manually.

What Yosemite Actually Does

Yosemite, named after the national park, is structured as a philanthropic science organisation rather than a for-profit biotech company. That distinction matters. A for-profit biotech needs to find commercially viable targets, drugs that can recoup clinical trial costs and generate profit for investors. A well-funded philanthropic organisation can take swings at problems that the market underserves, rare cancers, paediatric tumours, or drug combinations that fall outside standard treatment protocols because no single pharmaceutical company owns all the components.

The organisation works by partnering with academic research institutions and clinical centres to access patient data, which is then processed through machine learning pipelines to identify correlations between tumour characteristics and treatment responses. The goal is to generate hypotheses that human researchers can then test experimentally, rather than replacing researchers with algorithms.

This is a model that several other well-funded science philanthropies have explored, and there are genuine successes to point to. The Broad Institute's work on genomic medicine and the Chan Zuckerberg Biohub's approach to infectious disease have both demonstrated that money plus computational power plus access to good data can move faster than traditional pharmaceutical development cycles in certain domains.

The AI Angle Is Real, Not Just Hype

It would be easy to dismiss this as another tech-adjacent foundation throwing fashionable AI language at a hard problem. But the computational biology field has genuinely matured in the last five years. AlphaFold's protein structure predictions, first published in 2020 and continuously refined since, changed what is computationally possible in drug discovery. Models trained on large genomic datasets can now identify potential drug targets with a specificity that would have taken decades of wet-lab work to achieve through traditional methods.

The honest caveat is that identifying a promising target computationally is a very different challenge from getting a drug through clinical trials. The failure rate in oncology drug development is notoriously high, somewhere around 90 percent of compounds that show promise in early trials fail before reaching patients. Computational tools can improve the quality of the hypotheses you start with, but they cannot eliminate the fundamental biological complexity of cancer.

Reed Jobs has spoken publicly about being motivated by personal loss. His father, Steve Jobs, died of pancreatic cancer in 2011 at the age of 56, a disease with a five-year survival rate that has barely improved in decades despite significant research investment. That personal history gives Yosemite a particular emotional weight, though Jobs himself seems wary of leaning on it as a justification for the work.

The Harder Question

The most interesting tension in Yosemite's mission is one that applies to all private science philanthropy: who decides what gets researched? The National Cancer Institute, for all its bureaucracy, operates with a degree of peer review and public accountability. A private organisation, however well-intentioned, reflects the priorities and beliefs of its founders. If Reed Jobs believes a particular computational approach is most promising, Yosemite will pursue it. That agility is an advantage. But it also means there is no external check on whether the bets being placed are the right ones.

None of that is a reason not to try. Cancer kills approximately 10 million people per year globally, and the current pace of progress, while real, is not remotely fast enough. More bets, intelligently placed, with serious computational resources behind them, is probably net positive. Reed Jobs just does not want you to remember his dad when you think about it.